For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) closed at $32.35 in the last session, down -0.89% from day before closing price of $32.64. In other words, the price has decreased by -$0.89 from its previous closing price. On the day, 9.0 million shares were traded. TEVA stock price reached its highest trading level at $32.755 during the session, while it also had its lowest trading level at $32.0.
Ratios:
We take a closer look at TEVA’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 147.70. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 1.11. In the meantime, Its Debt-to-Equity ratio is 2.35 whereas as Long-Term Debt/Eq ratio is at 2.35.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $35.
On December 05, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.
On June 06, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $24.Goldman initiated its Buy rating on June 06, 2025, with a $24 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 16 ’25 when Weiss Amir sold 12,300 shares for $30.20 per share. The transaction valued at 371,504 led to the insider holds 5,650 shares of the business.
MIGNONE ROBERTO sold 77,400 shares of TEVA for $2,340,646 on Dec 16 ’25. The Director now owns 367,600 shares after completing the transaction at $30.24 per share. On Dec 12 ’25, another insider, Bridger Management, LLC (1), who serves as the Shareholder of the company, bought 150,000 shares for $30.18 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 37114589184 and an Enterprise Value of 52006588416. As of this moment, Teva-‘s Price-to-Earnings (P/E) ratio for their current fiscal year is 52.83, and their Forward P/E ratio for the next fiscal year is 11.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20 while its Price-to-Book (P/B) ratio in mrq is 5.12. Its current Enterprise Value per Revenue stands at 3.1 whereas that against EBITDA is 11.323.
Stock Price History:
The Beta on a monthly basis for TEVA is 0.70, which has changed by 0.4890511 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, TEVA has reached a high of $33.42, while it has fallen to a 52-week low of $12.47. The 50-Day Moving Average of the stock is 13.70%, while the 200-Day Moving Average is calculated to be 60.85%.
Shares Statistics:
According to the various share statistics, TEVA traded on average about 11.00M shares per day over the past 3-months and 10950090 shares per day over the past 10 days. A total of 1.15B shares are outstanding, with a floating share count of 1.14B. Insiders hold about 0.16% of the company’s shares, while institutions hold 57.64% stake in the company. Shares short for TEVA as of 1767139200 were 32862069 with a Short Ratio of 2.99, compared to 1764288000 on 45620941. Therefore, it implies a Short% of Shares Outstanding of 32862069 and a Short% of Float of 2.8800000999999997.
Earnings Estimates
. The current rating of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is the result of assessments by 9.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.59, with high estimates of $0.63 and low estimates of $0.54.
Analysts are recommending an EPS of between $2.77 and $2.55 for the fiscal current year, implying an average EPS of $2.63. EPS for the following year is $2.77, with 13.0 analysts recommending between $2.94 and $2.53.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $4.33B. It ranges from a high estimate of $4.52B to a low estimate of $4.14B. As of. The current estimate, Teva- Pharmaceutical Industries Ltd. ADR’s year-ago sales were $4.23BFor the next quarter, 9 analysts are estimating revenue of $3.97B. There is a high estimate of $3.97B for the next quarter, whereas the lowest estimate is $3.97B.
A total of 11 analysts have provided revenue estimates for TEVA’s current fiscal year. The highest revenue estimate was $17.15B, while the lowest revenue estimate was $16.68B, resulting in an average revenue estimate of $16.92B. In the same quarter a year ago, actual revenue was $16.54BBased on 2 analysts’ estimates, the company’s revenue will be $16.96B in the next fiscal year. The high estimate is $16.98B and the low estimate is $16.95B.
